Skip to main content
Erschienen in: Intensive Care Medicine 2/2003

01.02.2003 | Brief Report

The use of the activated clotting time for monitoring heparin therapy in critically ill patients

verfasst von: Jan J. De Waele, Sebastiaan Van Cauwenberghe, Eric Hoste, Dominique Benoit, Francis Colardyn

Erschienen in: Intensive Care Medicine | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the correlation between activated clotting time (ACT) and activated partial thromboplastin time (aPTT) in patients receiving intravenous unfractionated heparin therapy, and the accuracy of the ACT in predicting the level of anticoagulation.

Design

Paired aPTT and ACT measurements were obtained from a convenience sample of critically ill patients requiring intravenous unfractionated heparin. The aPTT was determined in the hospital laboratory and ACT measurements were performed with a portable device.

Setting

The intensive care unit of Ghent University Hospital, a tertiary care facility with 54 beds.

Patients and participants

Twenty-eight patients were studied prospectively; a total of 105 paired samples were obtained. The indication for heparin therapy was cerebral ischemia in 8, various cardiac conditions in 10, pulmonary embolism in 3, continuous hemofiltration in 3, and peripheral arterial thrombosis in 4.

Results

There was a significant correlation between aPTT and ACT. Analysis of variance showed a significant difference in ACT between different levels of anticoagulation, aPTT shorter than 60 s (group 1), aPTT 60–90 s (group 2), and aPTT longer than 90 s (group 3): 142±16.7 s in group 1 vs. 155±29.6 and 192±39.1 in groups 2 and 3.

Conclusions

The correlation between the aPTT and the ACT in this ICU setting is poor; ACT cannot differentiate between low and therapeutic levels of anticoagulation. The use of the ACT for monitoring low to moderate doses of heparin in ICU patients cannot be recommended.
Literatur
1.
Zurück zum Zitat Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMed Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMed
2.
Zurück zum Zitat Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W (2000) Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21:1406–1432CrossRefPubMed Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W (2000) Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21:1406–1432CrossRefPubMed
3.
4.
Zurück zum Zitat Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224–2228PubMed Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224–2228PubMed
5.
Zurück zum Zitat Hirsh J, Dalen JE, Deykin D, Poller L (1992) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102:337S-351SPubMed Hirsh J, Dalen JE, Deykin D, Poller L (1992) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102:337S-351SPubMed
6.
Zurück zum Zitat Simko RJ, Tsung FF, Stanek EJ (1995) Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 29:1015–1021PubMed Simko RJ, Tsung FF, Stanek EJ (1995) Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 29:1015–1021PubMed
7.
Zurück zum Zitat O'Neill AI, McAllister C, Corke CF, Parkin JD (1991) A comparison of five devices for the bedside monitoring of heparin therapy. Anaesth Intensive Care 19:592–596PubMed O'Neill AI, McAllister C, Corke CF, Parkin JD (1991) A comparison of five devices for the bedside monitoring of heparin therapy. Anaesth Intensive Care 19:592–596PubMed
8.
Zurück zum Zitat Reiner JS, Coyne KS, Lundergan CF, Ross AM (1994) Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49–52PubMed Reiner JS, Coyne KS, Lundergan CF, Ross AM (1994) Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49–52PubMed
9.
Zurück zum Zitat Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B (1993) On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 71:469–471PubMed Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B (1993) On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 71:469–471PubMed
10.
Zurück zum Zitat Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ (1993) Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 9:797–801PubMed Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ (1993) Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 9:797–801PubMed
11.
Zurück zum Zitat Uden DL, Payne NR, Kriesmer P, Cipolle RJ (1989) Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med 17:1048–1051PubMed Uden DL, Payne NR, Kriesmer P, Cipolle RJ (1989) Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med 17:1048–1051PubMed
12.
Zurück zum Zitat Estes JW (1975) The laboratory control of heparin therapy. Curr Ther Res Clin Exp 18:58–65PubMed Estes JW (1975) The laboratory control of heparin therapy. Curr Ther Res Clin Exp 18:58–65PubMed
13.
Zurück zum Zitat Banez EI, Triplett DA, Koepke J (1980) Laboratory monitoring of heparin therapy-the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol 74:569–574PubMed Banez EI, Triplett DA, Koepke J (1980) Laboratory monitoring of heparin therapy-the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol 74:569–574PubMed
14.
Zurück zum Zitat Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56PubMed Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56PubMed
15.
Zurück zum Zitat Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J (1997) Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24–28PubMed Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J (1997) Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24–28PubMed
16.
Zurück zum Zitat Marci CD, Prager D (1993) A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 99:546–550PubMed Marci CD, Prager D (1993) A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 99:546–550PubMed
Metadaten
Titel
The use of the activated clotting time for monitoring heparin therapy in critically ill patients
verfasst von
Jan J. De Waele
Sebastiaan Van Cauwenberghe
Eric Hoste
Dominique Benoit
Francis Colardyn
Publikationsdatum
01.02.2003
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 2/2003
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-002-1609-7

Weitere Artikel der Ausgabe 2/2003

Intensive Care Medicine 2/2003 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.